Clinical Trial Update: Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial compares afatinib versus erlotinib as second TKI therapy after failure of a first TKI and chemotherapy in metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Afatinib (afatinib)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: The University of Hong Kong | Conditions: Lung Cancer | Phase 2 | Status: COMPLETED